Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) and DiaMedica Therapeutics Inc. (NASDAQ:DMAC) compete against each other in the Biotechnology sector. We will contrast them and contrast their analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alder BioPharmaceuticals Inc. | 12 | 0.00 | N/A | -4.78 | 0.00 |
| DiaMedica Therapeutics Inc. | 3 | 66.04 | N/A | -0.92 | 0.00 |
Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.
Profitability
Table 2 shows us the net margins, return on equity and return on assets of both companies.
| Net Margins | Return on Equity | Return on Assets | |
| Alder BioPharmaceuticals Inc. | 0.00% | -193.2% | -67.2% |
| DiaMedica Therapeutics Inc. | 0.00% | 0% | 0% |
Analyst Ratings
The table shown features the ratings and recommendations for Alder BioPharmaceuticals Inc. and DiaMedica Therapeutics Inc.
| Sell Ratings | Hold Ratings | Buy Ratings | Rating Score | |
| Alder BioPharmaceuticals Inc. | 0 | 5 | 0 | 2.00 |
| DiaMedica Therapeutics Inc. | 0 | 0 | 0 | 0.00 |
The upside potential is 1.39% for Alder BioPharmaceuticals Inc. with average price target of $18.9.
Insider & Institutional Ownership
Alder BioPharmaceuticals Inc. and DiaMedica Therapeutics Inc. has shares owned by institutional investors as follows: 0% and 13.72%. 0.1% are Alder BioPharmaceuticals Inc.’s share owned by insiders. Comparatively, DiaMedica Therapeutics Inc. has 8.37% of it’s share owned by insiders.
Performance
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
| Performance (W) | Performance (M) | Performance (Q) | Performance (HY) | Performance (Y) | Performance (YTD) | |
| Alder BioPharmaceuticals Inc. | -4.44% | -14.45% | -18.65% | -28.33% | -43.62% | -1.27% |
| DiaMedica Therapeutics Inc. | -0.53% | -23.25% | 11.93% | -2.51% | -54.51% | 28.18% |
For the past year Alder BioPharmaceuticals Inc. had bearish trend while DiaMedica Therapeutics Inc. had bullish trend.
Summary
On 5 of the 8 factors DiaMedica Therapeutics Inc. beats Alder BioPharmaceuticals Inc.
Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes therapeutic antibodies in the United States, Australia, and Ireland. The companyÂ’s lead product candidate includes ALD403, an antibody, which is in Phase II clinical trial to target calcitonin gene-related peptide for the prevention of migraine. It also develops ALD1910, a genetically engineered monoclonal antibody that is in preclinical study for the treatment of migraine; and Clazakizumab, an antibody, which has been completed Phase IIb clinical trial that inhibits the pro-inflammatory cytokine interleukin-6 for the treatment of rheumatoid and psoriatic arthritis. In addition, the company has preclinical programs in the discovery phase for various indications. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
